These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26897044)

  • 1. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer.
    Rosati G; Aprile G; Cardellino GG; Avallone A
    J Geriatr Oncol; 2016 Mar; 7(2):134-41. PubMed ID: 26897044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
    Peeters M; Price T; Van Laethem JL
    Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular target therapy and chemotherapy for advanced colorectal cancer].
    Nakashima K; Yamazaki K; Boku N
    Gan To Kagaku Ryoho; 2008 May; 35(5):725-30. PubMed ID: 18487907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
    Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of antibodies for colorectal cancer chemotherapy].
    Kanemitsu K; Kakeji Y
    Nihon Rinsho; 2014 Jan; 72(1):114-9. PubMed ID: 24597358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
    Woo J; Palmisiano N; Tester W; Leighton JC
    Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.
    Wainberg ZA; Drakaki A
    Expert Opin Biol Ther; 2015; 15(8):1205-20. PubMed ID: 26066903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
    Lien K; Berry S; Ko YJ; Chan KK
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
    Hendifar A; Tan CR; Annamalai A; Tuli R
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.